Genelux Corporation
GNLXGenelux Corporation (GNLX), a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies, reported a net loss of $32.1 million for FY 2025, up 7.6% YoY from $29.9 million in FY 2024, driven by higher operating expenses of $33.2 million versus $31.7 million prior year.
NASDAQ
Healthcare
Biotechnology
$2.56
+0.01(0.2%)
52W $2.08 – $8.24
AI-generated
Genelux Corporation (GNLX), a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies, reported a net loss of $32.1 million for FY 2025, up 7.6% YoY from $29.9 million in FY 2024, driven by higher operating expenses of $33.2 million versus $31.7 million prior year.
$96MMkt Cap
$8.1KRev TTM
-$33MNI TTM
-2.9xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 18, 2026Genelux Corporation (GNLX), a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies, reported a net loss of $32.1 million for FY 2025, up 7.6% YoY from $29.9 million in FY 2024, driven by higher operating expenses of $33.2 million versus $31.7 million prior year. Revenue remained negligible at $8K, consistent YoY, from a minor licensing agreement. Research and development expenses rose...
What Changed Recently
Fundamentals
How The Business Makes Money
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Industry Biotechnology
Analyst View
Company Profile
CIK0001231457
ISINUS36870H1032
Phone858 483 0024
Address2625 Townsgate Road, Westlake Village, CA, 91361, US
SEC EDGAR